Legend Biotech (LEGN)
(Real Time Quote from BATS)
$46.30 USD
+1.00 (2.21%)
Updated Apr 29, 2024 10:30 AM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Income Statements
Fiscal Year end for Legend Biotech Corporation Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 285 | 117 | 93 | 82 | 64 |
Cost Of Goods | 144 | 65 | 0 | 0 | 0 |
Gross Profit | 141 | 52 | 93 | 82 | 64 |
Selling & Adminstrative & Depr. & Amort Expenses | 554 | 507 | 472 | 305 | 195 |
Income After Depreciation & Amortization | -413 | -456 | -379 | -223 | -130 |
Non-Operating Income | -108 | 10 | -7 | -84 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -520 | -446 | -386 | -308 | -130 |
Income Taxes | -2 | 1 | 0 | -4 | 3 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -518 | -446 | -386 | -303 | -133 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -518 | -446 | -386 | -303 | -133 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -392 | -437 | -365 | -213 | -125 |
Depreciation & Amortization (Cash Flow) | 20 | 18 | 14 | 10 | 5 |
Income After Depreciation & Amortization | -413 | -456 | -379 | -223 | -130 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 352.17 | 318.08 | 281.70 | 236.31 | NA |
Diluted EPS Before Non-Recurring Items | -1.23 | -1.30 | -1.35 | -0.94 | NA |
Diluted Net EPS (GAAP) | -2.94 | -2.80 | -2.74 | -2.56 | -1.32 |
Fiscal Year end for Legend Biotech Corporation Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 79.46 | 96.01 | 73.33 | 36.34 |
Cost Of Goods | NA | NA | 43.48 | NA | 35.61 |
Gross Profit | NA | NA | 52.53 | NA | 0.72 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 109.36 | 0.00 | 127.58 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | -56.83 | 0.00 | -126.86 |
Non-Operating Income | NA | NA | -5.68 | NA | 14.89 |
Interest Expense | NA | NA | 0.00 | NA | NA |
Pretax Income | NA | NA | -62.50 | NA | -111.97 |
Income Taxes | NA | NA | -0.29 | NA | 0.13 |
Minority Interest | NA | NA | 0.00 | NA | NA |
Investment Gains/Losses | NA | NA | 0.00 | NA | NA |
Other Income/Charges | NA | NA | 0.00 | NA | NA |
Income From Cont. Operations | NA | -144.82 | -62.21 | -199.13 | -112.10 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -144.82 | -62.21 | -199.13 | -112.10 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 363.66 | 363.08 | 350.52 | 330.50 |
Diluted EPS Before Non-Recurring Items | NA | -0.40 | -0.17 | -0.27 | -0.40 |
Diluted Net EPS (GAAP) | NA | -0.40 | -0.34 | -0.57 | -0.34 |